Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

This study is testing whether combining microwave ablation (a procedure that uses heat to destroy tumors) with lenvatinib (a targeted drug) is more effective than ablation alone for treating recurrent liver cancer (HCC). **You may be eligible if...** - You have primary liver cancer (HCC) that has come back after prior treatment - You have 3 or fewer tumors, each no larger than 5 cm - You are between 18 and 75 years old - Your liver function is preserved (Child-Pugh A or mild B) - Your blood counts and organ function are within acceptable ranges - Your overall health is good (KPS score 90 or above) **You may NOT be eligible if...** - Your cancer has spread into major blood vessels or outside the liver - You have had a prior different cancer - You are unwilling to participate in follow-up - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.